KOSDAQBiotech & Pharma195940

HK inno.N

₩40,250▼ 0.86%2026-10-02 close

Market Cap

₩1.1T

Turnover

₩1.6B

Volume

40,000 shares

Shares out.

28.3M

PER

13.9×

PBR

0.9×

EPS

₩3,030

Dividend Yield

0.98%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩410 per share · Prices as of the 2026-10-02 close

Report overview

K-CAB Lifts Margins; Next Gates Are the US and Europe

A single product, K-CAB, has lifted profits faster than sales, while two pending events - the US regulatory review and a European licensing deal - will shape the next phase.

1
2025 consolidated revenue reached KRW 1,063.1bn with operating profit of KRW 110.8bn, the first year above the KRW 1trn mark, and the operating margin improved for four straight years from 6.2% in 2022 to 10.4% in 2025.
2
From Q1 2026 the company shifted K-CAB volume-linked price rebates from a cost deduction to a revenue deduction, which suppressed reported top-line growth while flattering the margin line.
3
Braintree Laboratories, an affiliate of US partner Sebela Pharmaceuticals, filed the K-CAB new drug application with the FDA in January 2026, and the company has said it expects approval around January 2027.
4
The European licensing-out deal remains under negotiation, with reports indicating that talks over deal size and scope of rights have pushed back signing.
5
Counterweights include competition from Jaqbo and Fexuclue in the domestic P-CAB market, the generic reference price cut enacted in March 2026, and the thin profit contribution from the health and beauty division.

Business structure

HK inno.N's core operations are the manufacture and sale of ethical (prescription) drugs, or ETC, and health and beauty (H&B) products; the company was acquired by Korea Kolmar in April 2018 and listed on the KOSDAQ market in August 2021.

As of Q1 2026 the ETC division accounted for 92.4% of company-wide revenue versus 7.6% for H&B, so the earnings profile is effectively that of a prescription pharmaceutical company. In the same quarter ETC revenue was KRW 239.1bn with operating profit of KRW 33.1bn, delivering nearly all of the company's profit.

By product, the gastroesophageal reflux disease drug K-CAB was largest at KRW 45.6bn, followed by IV solutions at KRW 37.1bn, Epokine at KRW 10.7bn and Rovazet at KRW 10.5bn.

Flagship product K-CAB, Korea's 30th domestically developed new drug, launched in March 2019 and posted KRW 20.8bn of outpatient prescriptions in April 2026 on UBIST data, ranking first among the 10,476 products tracked.

Overseas it has entered 55 countries via technology licensing or finished-product exports and has secured approval in 23 countries including Korea. The revenue model therefore combines domestic prescriptions, finished-product exports and partner royalties or milestone income, so one molecule generates several streams.

Within ETC, IV solutions grew 16.1% to KRW 141.7bn in 2025 and oncology sales including Roche's Avastin expanded to around KRW 30.0bn, broadening the portfolio.

By contrast, the H&B division, which handles brands such as Condition, still has to escape the loss-making structure created by a product recall, and Q1 2026 H&B revenue fell 8.4% to KRW 19.6bn from KRW 21.4bn a year earlier while operating profit shrank from KRW 1.8bn to KRW 0.1bn.

Earnings trend

Quarterly revenue · Operating profit

₩263.1B₩19.5B25Q2₩260.8B₩25.9B25Q3₩291.9B₩40.1B25Q4₩258.7B₩33.2B26Q1₩267.2B₩30B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩846.5B₩52.5B2022₩828.9B₩65.9B2023₩897.1B₩88.2B2024₩1.1T₩110.9B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩263.1B	₩19.5B	7.4%
2025Q3	₩260.8B	₩25.9B	9.9%
2025Q4	₩291.9B	₩40.1B	13.7%
2026Q1	₩258.7B	₩33.2B	12.8%
2026Q2	₩267.2B	₩30B	11.2%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩846.5B	₩52.5B	₩38.1B	6.2%	3.3%	54.9%
2023	₩828.9B	₩65.9B	₩47.2B	8.0%	3.9%	53.5%
2024	₩897.1B	₩88.2B	₩61.6B	9.8%	4.9%	51.0%
2025	₩1.1T	₩110.9B	₩75.7B	10.4%	5.7%	57.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-09-04

Earnings analysis

For 2025 the company reported consolidated revenue of KRW 1,063.1bn, operating profit of KRW 110.8bn and net profit attributable to owners of KRW 75.7bn, crossing the KRW 1trn revenue mark for the first time.

Over four years revenue slipped from KRW 846.5bn in 2022 to KRW 828.9bn in 2023 before expanding to KRW 897.1bn in 2024 and KRW 1,063.1bn in 2025, while the operating margin improved each year from 6.2% to 8.0%, 9.8% and 10.4%.

Operating cash flow rose from KRW 58.6bn in 2022 to KRW 83.0bn, KRW 105.9bn and KRW 162.0bn, so profit growth translated into cash.

On a quarterly basis Q4 2025 was the strongest of the last five quarters at KRW 291.9bn of revenue and KRW 40.1bn of operating profit, a 13.7% margin, followed by KRW 258.7bn and KRW 33.2bn in Q1 2026 and KRW 267.2bn and KRW 30.0bn in Q2 2026, keeping margins in double digits.

Q2 2026 revenue rose only slightly from KRW 263.1bn a year earlier, but operating profit climbed from KRW 19.5bn to KRW 30.0bn and the operating margin improved 3.8 percentage points from 7.4% to 11.2%.

The muted top-line growth reflects the accounting change made from Q1 2026, under which K-CAB volume-linked price rebates moved from a cost deduction to a revenue deduction.

Underlying demand indicators moved the other way: domestic K-CAB prescriptions were KRW 61.5bn in Q2 2026 and finished-product exports were KRW 4.5bn, up from KRW 1.1bn a year earlier.

However, in Q2 2026 operating profit fell 9.6% and net profit fell 47.3% versus the previous quarter, taking net profit attributable to owners to KRW 13.7bn from KRW 25.9bn in Q1, so the swing below the operating line was larger than at the operating level.

On the balance sheet, equity grew from KRW 1,251.4bn in 2024 to KRW 1,328.4bn in 2025, yet the debt-to-equity ratio rose from 51.0% to 57.9%.

Industry analysis

The center of gravity in Korea's peptic ulcer drug market has shifted from the older PPI class toward the P-CAB class. According to Korea IR Service analysis, the P-CAB class lifted its domestic market share from 2.2% in 2019 to 22.3% within six years of launch.

As the market has grown, however, so has late-entrant competition.

In Q1 2026 domestic sales ranked K-CAB at KRW 45.6bn, Onconic Therapeutics' Jaqbo at KRW 28.5bn and Daewoong Pharmaceutical's Fexuclue at KRW 19.1bn, and Jaqbo, despite being the last P-CAB to launch, overtook Fexuclue in monthly outpatient prescriptions from April, prompting commentary that the domestic P-CAB market is entering maturity.

On policy, the government cut the generic reference price from 53.55% to 45% of the originator price in March 2026, and DS Investment & Securities said in a July 2026 report that, allowing for the innovative pharmaceutical company exemption, the impact should be limited through 2029 and equate to roughly a 3-4% revenue loss on a 2027 basis.

Overseas, China proved the commercial case first: royalty income from China is estimated to have grown from about KRW 7.0bn in 2024 to around KRW 14.0bn for 2025.

The US, by contrast, currently has only Voquezna selling in the P-CAB class, so an incumbent already holds the ground, and with low-priced PPI generics widely prescribed and payers highly influential, observers note that approval does not automatically translate into prescription growth.

In short, intensifying competition and price pressure at home are operating at the same time as royalty expansion and new market entry abroad.

Outlook

The nearest item to verify is the US regulatory timeline.

Braintree Laboratories, an affiliate of US partner Sebela Pharmaceuticals, filed the K-CAB new drug application with the FDA on 9 January 2026 local time; the company said it expects US marketing approval in January 2027; and the filing targets simultaneous approval of three indications - non-erosive reflux disease, erosive esophagitis treatment and erosive esophagitis maintenance therapy.

The clinical basis presented was phase 3 data in 1,250 erosive esophagitis patients disclosed at Digestive Disease Week in May 2026, the first P-CAB-class result to demonstrate superiority over a PPI, and Sebela has said it plans to present the full clinical program results at major international conferences and publish them in journals.

On the second axis, Europe, licensing negotiations aimed at major EU markets such as Germany and France are under way, and signing is reported to have slipped as talks over deal size, scope of rights and development strategy have dragged on.

On capacity, a May 2026 disclosure approved a KRW 97.0bn investment - 7.3% of equity - in a new solid oral dosage production facility of 12,561.98 square meters on remaining land at the Osong plant in Chungbuk, running from 21 May 2026 to 31 January 2028.

On estimates, analyst Kim Min-jung of DS Investment & Securities projected in a July 2026 report full-year 2026 revenue of about KRW 1,090.4bn and operating profit of about KRW 132.7bn, premised on recovery in IV solutions and the H&B division.

The follow-on pipeline includes a JAK-1 inhibitor for autoimmune disease, a sarcopenia treatment, denosumab and nivolumab biosimilars and a smallpox vaccine, while a GLP-1RA injectable is in domestic phase 3 for obesity and diabetes indications.

That said, the heavy contribution from a single product means delays in US approval or European entry would push back the timing of global growth, price cuts and intensifying P-CAB competition are cited as burdens, and bringing forward the visible value of follow-on pipeline assets is regarded as a task.

Valuation

PER

13.9×

PBR

0.9×

ROE

6.5%

EPS

₩3,030

BPS

₩47,676

Dividend per share

₩410

The earnings trend can be summarized as four consecutive years of operating margin improvement and double-digit operating margins across the last five quarters, with cash flow moving in the same direction.

The share price sits modestly below reported book value per share, so relative to assets the multiple is not demanding given the higher profit base.

The earnings-based multiple is lower than the expectation-driven multiples often seen among listed Korean pharmaceutical and biotech names, which reflects a business that is actually booking profits.

Dividends have been declared once a year in cash, and the payout decided in March 2026 carried a dividend-to-price ratio of under 1%, with a record date of 31 March - below what income-oriented investors typically look for.

For reference, KB Securities maintained a Buy rating and a target price of KRW 77,000 in a July 2026 report, stating that the target was derived using a discounted cash flow approach and corresponds to roughly 20 times expected earnings over the next twelve months and 13 times EV/EBITDA.

Those multiple levels, however, depend heavily on how much of the unconfirmed US approval and European deal events is embedded, so whether those events land or slip remains the variable that changes how the multiple should be read.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-09-04

Bull factors

Profit improving faster than sales, and structurally visible

The operating margin rose for four consecutive years from 6.2% in 2022 to 8.0%, 9.8% and 10.4%, and it has stayed in double digits for the three quarters from Q4 2025. Operating cash flow also expanded from KRW 58.6bn in 2022 to KRW 162.0bn in 2025, so the profit improvement was not confined to accounting lines.

In Q2 2026, even with the headwind of co-promotion arrangements on existing products ending, licensing income and K-CAB offset the loss. The core bull argument is that the gap between revenue growth and profit growth has stayed wide.

K-CAB's domestic prescription strength and export diversification

On UBIST data K-CAB recorded KRW 20.8bn of outpatient prescriptions in April 2026, ranking first among 10,476 tracked products, and it is the only domestically developed new drug in the top ten.

In Q2 2026 domestic prescriptions reached KRW 61.5bn and finished-product exports rose to KRW 4.5bn from KRW 1.1bn a year earlier.

Company IR materials noted that the number of export destination countries rose from 18 to 22 within a year, that Russia moved to launched status in March 2026 and that Belarus was newly added to the approval list. The domestic prescription base and the widening export footprint are advancing in parallel.

Repeatedly confirmed China royalties, plus US and Europe options

Royalty income from China is estimated to have grown from about KRW 7.0bn in 2024 to roughly KRW 14.0bn for 2025.

In China the drug is sold as Taixinzan, with local sales of about KRW 190.0bn in 2025 and Q1 2026 royalties of roughly KRW 4.0bn, double the year-earlier figure, while partner Luoxin Pharmaceutical has been widening insurance coverage including listing for Helicobacter pylori eradication therapy.

Industry observers argue that if US approval and a European licensing deal both land, K-CAB's global business structure would be essentially complete. In effect, two unconfirmed options sit on top of a royalty stream that is already generating cash.

Bear factors

Single-product concentration and event slippage risk

As of Q1 2026, K-CAB accounted for 17.6% of total revenue, with IV solutions next at 14.3%. Because one product contributes so much of revenue, commentators note that a delay in US approval or European entry would also push back global growth momentum.

European licensing talks are under way but signing is reported to be running late as deal size and scope of rights are negotiated. The more the case rests on events, the more schedule changes alone can unsettle earnings visibility.

Intensifying domestic P-CAB competition and maturity signals

In Q1 2026 K-CAB stayed first domestically at KRW 45.6bn, but Onconic Therapeutics' Jaqbo at KRW 28.5bn and Daewoong Pharmaceutical's Fexuclue at KRW 19.1bn were closing fast.

Jaqbo, the last to launch, overtook Fexuclue in monthly outpatient prescriptions from April, which was read as a sign that the domestic P-CAB market is entering maturity.

The number of companies developing generics is also rising, while the company won a second-instance ruling on its compound patent giving protection through 2031. The bear argument is that domestic demand alone is becoming a harder base on which to sustain growth.

Weak H&B division and rising financial burden

In Q1 2026 the H&B division's revenue fell 8.4% to KRW 19.6bn from KRW 21.4bn a year earlier, and operating profit dropped more than 94% from KRW 1.8bn to KRW 0.1bn.

How quickly the division escapes the loss structure created by the recall, and whether compensation talks with the manufacturer conclude, were flagged as the key issues.

The consolidated debt-to-equity ratio rose from 51.0% in 2024 to 57.9% in 2025, and borrowings and bond-type obligations maturing within a year were cited as a task. The KRW 97.0bn production facility investment running to January 2028 should also be viewed alongside this from a cash requirement standpoint.

Risk factors

Regulatory and approval risk

The US new drug application was filed in January 2026 and the company said it expects approval in January 2027, but the timing and the range of approved indications rest with the regulator.

The filing targets simultaneous approval of three indications, and the number of approved indications determines prescribing opportunities. The decision date itself is described as anywhere from late 2026 at the earliest to early 2027 at the latest. The possibility of information requests or schedule slippage during review is always present.

Drug pricing and policy risk

In March 2026 the government cut the generic reference price from 53.55% to 45% of the originator price.

DS Investment & Securities said in a July 2026 report that, because application is phased by listing year and innovative pharmaceutical companies receive an exemption, the impact should be limited through 2029 and equate to a 3-4% revenue loss on a 2027 basis.

In addition, volume-linked price rebates are now booked as a revenue deduction, so prescription growth does not translate fully into reported revenue.

Kim Seung-jun of Korea IR Service argued that until the various catalysts become visible, growth could stall structurally due to the rebate revenue deduction and government price cuts, requiring continuous monitoring.

Execution and capital spending risk

The company disclosed a KRW 97.0bn solid oral dosage production facility investment, equal to 7.3% of equity, running from May 2026 to January 2028. If the capacity addition does not coincide with demand expansion, fixed cost burdens may show up first.

Separately, observers noted that the IR page highlighting the target of 100 countries by 2028 and the R&D lines flagging phase 3 for a GLP-1 obesity drug and phase 2 entry for a JAK-1 atopic dermatitis candidate were absent from later decks.

When the frequency of disclosure and explanation on pipeline progress declines, the sheer amount of information investors can verify itself becomes a risk.

What to watch next

September to October 2026
DS Investment & Securities noted in a July 2026 report that details of the KOSDAQ promotion and demotion system were due to be released in September or October, and that HK inno.N is already included in the KOSDAQ Global Segment. When the detailed rules are published, the actual inclusion criteria and effective dates are the items to check.
Late October to early November 2026
Preliminary Q3 2026 results are due in this window. Beyond revenue and operating profit, the items to verify are the trend in domestic K-CAB prescriptions after the accounting change, the amount of China royalties recognized, the pace of recovery in IV solutions and whether the H&B division returns to profit.
Q4 2026
The item to watch is whether the European licensing deal for K-CAB targeting major EU markets such as Germany and France is signed, and on what terms. If signed, the upfront and milestone structure and scope of rights matter; if delayed, whether the reason appears in disclosures or IR materials is the point to check.
Late 2026 to January 2027
The core items are the US FDA decision, which the company has said it expects in January 2027, and how many of the three filed indications - non-erosive reflux disease, erosive esophagitis treatment and maintenance therapy - are approved. The breadth of approved indications feeds directly into the subsequent prescribing base and royalty scale.
February to March 2027
This is the window for confirmed full-year 2026 results and the cash dividend decision. In the prior year the per-share cash dividend decision was disclosed in March with a record date of 31 March. The items to verify are whether the full-year operating margin holds around the 2025 level and whether progress and funding needs for the new Osong facility are presented alongside.

Overall view

HK inno.N posted 2025 consolidated revenue of KRW 1,063.1bn, operating profit of KRW 110.8bn and net profit attributable to owners of KRW 75.7bn, extending four consecutive years of operating margin improvement (6.2% to 8.0% to 9.8% to 10.4%), while operating cash flow expanded from KRW 58.6bn to KRW 162.0bn over the same period.

In 2026, the accounting change shifting K-CAB price rebates from a cost deduction to a revenue deduction suppressed reported top-line growth while lifting margins, and in Q2 revenue of KRW 267.2bn and operating profit of KRW 30.0bn came with an operating margin up from 7.4% a year earlier to 11.2%.

The bull case rests on the dominance of the top-prescribed domestic product, repeatedly confirmed China royalties and two unconfirmed options in the US and Europe; the bear case rests on concentration, with K-CAB at 17.6% of company revenue in Q1 2026, the pursuit by Jaqbo and Fexuclue and signs of maturity in the domestic P-CAB market, plus the weak H&B division and a higher debt-to-equity ratio.

On policy, the generic reference price cut enacted in March 2026 remains a medium-term variable.

The likely order of verification from here is the Q3 trend in K-CAB prescriptions, China royalties, IV solutions and H&B, then whether the European licensing deal is signed, and then the US approval decision that the company has said it expects in January 2027. This report is for information purposes only and contains no buy or sell opinion and no target price.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.